Form 4: Mineralys Therapeutics' Chief Medical Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On July 16, 2024, David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, Inc., executed a stock option to acquire 525 shares of common stock at a price of $1.08 per share.
- Simultaneously, Rodman sold 525 shares of common stock at a weighted-average price of $15.0011 per share, with individual transactions ranging from $15.00 to $15.01.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 14, 2023.
- Following these transactions, Rodman directly owns 102,873 shares of Mineralys Therapeutics common stock and holds options for 183,483 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the transactions were pre-planned to avoid accusations of trading on inside information. Such plans are common among corporate executives.
Key Dates
| Date | Description |
|---|---|
| February 9, 2023 | Date of Reporting Person's Form 3 filing. |
| July 12, 2023 | Date when 25% of the underlying shares of the stock option vested. |
| November 14, 2023 | Date the reporting person adopted the Rule 10b5-1 trading plan. |
| July 16, 2024 | Date of the reported transactions: exercising stock options and selling shares. |
| July 18, 2024 | Date of the Form 4 filing. |
| July 11, 2032 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.